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 NHERF1 – NEW MODIFIER OF COLORECTAL CANCER PROGRESSION 
 
Publication No.__________ 
Yuho Hayashi, M.Sc. 
Supervisory Professor: Maria-Magdalena Georgescu, M.D., Ph.D. 
 
Colorectal cancer (CRC) develops from multiple progressive modifications of normal 
intestinal epithelium into adenocarcinoma. Loss of cell polarity has been implicated as an 
early event in this process, but the molecular players involved are not well known. NHERF1 
(Na+/H+ Exchanger Regulatory Factor 1) is an adaptor protein with apical membrane 
localization in polarized epithelia. In this study, we tested our hypothesis that NHERF1 
plays a role in CRC. We examined surgical CRC resection specimens for changes in 
NHERF1 expression, and modeled these changes in two- and three-dimensional (2D and 3D) 
Caco-2 CRC cell systems. NHERF1 had significant alterations from normal to adenoma and 
carcinoma transitions (χ2=38.5, d.f.=4, P<0.001), displaying apical membrane localization in 
normal tissue but loss of expression in adenoma and ectopic overexpression in carcinoma. In 
Caco-2 cell models, NHERF1 depletion induced epithelial-mesenchymal-transition in 2D 
cell monolayers and disruption of apical-basal polarity in 3D cyst system. The mesenchymal 
phenotype of NHERF1-depleted cells was fully restored by re-expression of NHERF1 at the 
apical membrane. Cytoplasmic and nuclear NHERF1 re-expression not only failed to restore 
the epithelial phenotype but led to more aggressive phenotypes. Our findings suggest that 
membrane NHERF1 is an important regulator of epithelial morphogenesis, and that changes 
in NHERF1 expression correlate with CRC progression. NHERF1 loss and ectopic 
expression that induce massive disruption of epithelial cell polarity may, thereby, mark 
important steps in CRC development. 
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CHAPTER 1 
 
INTRODUCTION 
 
1 
 1.1  Colorectal cancer 
 
Colorectal cancer (CRC), also known as large bowel cancer, is the fourth 
common type of cancer in the United States. The lifetime risk of CRC is 1 in 20 (5%) for 
both men and women. In 2009 alone, 147,000 new cases were diagnosed, as were 50,000 
deaths due to CRC reported (Jemal et al., 2009). The etiology of CRC remains unclear, 
but multiple factors, including both hereditary and environmental influences, are posited 
to play roles. In particular, the incidence of CRC has long been recognized to increase 
steeply after middle age (FIGURE 1.1); and this has been thought to relate to the multi-
stage theory of carcinogenesis as postulated over 50 years ago (Armitage and Doll, 1954; 
Foulds, 1954). On the basis of kinetic data that the incidence of human cancer is 
increased by 103-107-folds over age, it has been taken to require three to seven rate-
limiting events, or four to six decades of human lifetime, before cancer becomes 
clinically manifest (Vogelstein and Kinzler, 1993). The American Cancer Society (ACS) 
currently recommends men and women over age 50 to have screening colonoscopy 
every 10 years, or less invasive alternatives, such as sigmoidoscopy, CT (computed 
tomography) colonoscopy, and double-contrast barium enema every 5 years, for 
prevention and/or early detection of CRC (Walsh and Terdiman, 2003; Yeatman, 2003) 
(FIGURE 1.2).  
 
1.2  Genomic instability in colorectal cancer 
 
Most human CRC is considered a non-inherited condition, yet it shows many 
features of genetic abnormalities such  as microsatellite  instability, aneuploidy  (changes 
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FIGURE 1.1 The risk of colorectal cancer by different age groups. Note steep increases in 
the risk of colorectal cancer (CRC) for both men and women after age 40-59 (Jemal et 
al., 2009). 
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FIGURE 1.2 Anatomy of the colon. Four sections of the colon: caecum/ascending, 
transverse, descending, and sigmoid, are shown. Note the rectum at the most distal 
portion of the colon. In colonoscopy, colon is endoscopically examined with a CCD or 
fiber optic camera from the rectum up to the distal small intestine. Less invasive 
alternatives to colonoscopy is sigmoidoscopy, which examines only from the rectum up 
to the sigmoid section of the colon; CT colonography uses images reconstructed from 
CT scans; and double-contrast barium enema, the X-ray scans. Reprinted with 
permission from Yeatman, Encyclopedia of Life Sciences, Macmillan Publishers Ltd,, 
2001. Copyright © 2001 Macmillan Publishers Ltd.    
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 in chromosome number), chromosome fusions, and gene amplifications (Lengauer et al., 
1998). A long-standing postulate has been that these abnormalities represent a mutator 
phenotype that underlies the development of tumor growth (Loeb, 1991). In a landmark 
study by Vogelstain et al., colorectal tumor specimens ranging in the stages of neoplastic 
development were assayed for KRAS mutation and allelic deletions of chromosomes 5, 7, 
and 18 (Vogelstein et al., 1988). The results indicated that the frequency of KRAS 
mutation increased from 9% in adenomas <1 cm in size to 58% in those over 1 cm; on 
the other hand, deletions of chromosome 5, 17, and 18 were each observed in selected 
stages of adenoma or carcinoma. A multi-step genetic model of CRC development has 
since been proposed to consist both of activating mutations in an oncogene and of losses 
of multiple tumor suppressor genes (Fearon and Vogelstein, 1990). A simplified two-
step model was re-drawn and presented in FIGURE 1.3.  
 
1.3  Loss of adenomatous polyposis coli 
 
One of the earliest altered genes in the development of CRC is the adenomatous 
polyposis coli (APC) (Fearon and Vogelstein, 1990; Powell et al., 1992). The APC gene 
localized on chromosome 5 (5q21) was initially identified as a chromosomal region 
deleted in rare familial adenomatous polyposis (FAP) syndrome (Bodmer et al., 1987; 
Leppert et al., 1987); incidentally, this locus is also frequently involved in the non-
familial form of CRC (Ashton-Rickardt et al., 1989; Solomon et al., 1987; Vogelstein et 
al., 1988). Nucleotide sequence analyses of FAP and non-familial CRC tumor specimens 
suggested that somatic mutations of the APC gene initiated the development of tumor 
growth  in both  cases; over  60% of  these mutations were  clustered in a  focal region in  
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FIGURE 1.3 A simplified two-step model of CRC development. CRC is developed in 
two distinct steps. In first step, normal epithelium is transformed into (benign) adenoma. 
This process is believed to involve oncogenic activation of the Wnt/β-catenin pathway; 
and, in most cases, occurs from inactivating mutation of the adenomatous polyposis coli 
(APC) gene. In some cases, however, activating mutation of β-catenin itself is also seen. 
In second step, other changes, such as mutation of KRAS and p53, promote 
transformation of adenoma into (invasive) carcinoma. Note also loss of cell polarity 
early in the transformation process. 
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  exon 15, and were predicted to result in truncations of the cellular APC gene product 
(Miyoshi et al., 1992).  
 
Currently the best known function of cellular APC protein is in acting as a 
negative regulator of β-catenin (Bienz and Clevers, 2000; Polakis et al., 1999). It appears 
that these two proteins closely interact, as has been shown that full-length, but not 
truncated, APC can be co-immunoprecipitated with β-catenin in CRC cells (Rubinfeld 
1993, Su 1993). Cytoplasmic β-catenin level is seen to be elevated in CRC cells in the 
absence of wild-type APC, but can be reduced by forced expression of exogenous 
protein (Munemitsu et al., 1995). The elevated intracellular β-catenin level in the 
absence of wild-type APC has been further associated with constitutive activation of the 
β-catenin/T cell factor (TCF)-dependent transcription (Korinek et al., 1997; Morin et al., 
1997). Among the target genes activated in this pathway are identified as c-Myc and 
cyclin D1 oncogenes (He et al., 1998; Tetsu and McCormick, 1999). A possible link 
between functional inactivation of APC, oncogenic activation of β-catenin, and the 
attending initiation of oncogenic growth was thereby implicated. 
 
1.4  Loss of epithelial cell polarity 
 
Intestinal epithelium has polarized structures, consisting of linearly arranged 
IECs with asymmetrically organized apical membrane, basolateral membrane, and tight 
junctions (zonula occludens) that separates them (FIGURE 1.4). There have been 
increasingly frequent mentions of the association between loss of epithelial polarity and 
the initiation of  tumor  growth  (Aranda  et  al.,  2008;  Feigin  and  Muthuswamy,  2009; 
7 
  
 
 
 
 
 
 
                                         
 
 
FIGURE 1.4 Polarized organization of intestinal epithelium. Intestinal epithelium has 
polarized structure. Note apical membrane, basolateral membrane, and tight junctions 
(zonula occudens) that separates the two membrane domains. Reprinted with permission 
from Junquiera and Carneiro, Basic Histology 11th edition, McGraw-Hill, 2005. 
Copyright © 2005 The McGraw-Hill Companies.    
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 Huang and Muthuswamy, 2010; Lee and Vasioukhin, 2008; Mullin, 2004). Although 
molecular details of the relationship between cell polarity and tumor growth are still 
mostly missing, studies in Drosophila have implicated the role of three basolateral 
polarity proteins Lgl, Dlg, and Scrib in linking the cell polarity and growth pathways 
(Bilder et al., 2000). Others, more recently, indicated alterations in the members of 
apical polarity complex in human cancer, such as those of Par3, Par6, and aPKC (Nolan 
et al., 2008; Regala et al., 2005; Zen et al., 2009). Another apically localized protein, 
Na+/H+ exchanger regulatory factor 1 (NHERF1), will be the subject of this study, as 
below. 
 
1.5  Na+/H+ exchanger regulatory factor 1 (NHERF1) 
 
1.5.1  NHERF adaptors 
 
NHERF1 (also known as NHE-RF) is a protein co-factor initially isolated for the 
regulation of Na+/H+ exchanger (NHE) activity from rabbit renal brush border 
membrane (BBM) (Weinman et al., 1993; Weinman et al., 1995). The cDNA analysis 
indicated that the NHERF1 gene (SLC9A3R1) encoded a 358-residue protein, with two 
elements of repeat (amino acids 11-101 and 150-241) in predicted amino acid sequences 
(Weinman et al., 1995). Subsequently, ezrin-radixin-moesin (ERM)-binding 
phosphoprotein of 50 kDa (EBP50) was identified as the human homolog of NHERF1, 
and found to contain two elements of repeat over two-thirds of its full-length molecule 
(amino acids 11-97 and 149-236) (Reczek et al., 1997). Database searches on these 
elements gave a number of matched results; among included in this list were rat brain 
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 post-synaptic density protein (PSD-95), Drosophila septate junction protein Discs Large 
(Dlg), and mouse tight junctions protein zonula occludin-1 (ZO-1). The repeat elements 
of NHERF1 were thereby identified as the PDZ (PSD-95/Dlg/ZO-1) domains. These are 
conserved protein modules that form a small binding pocket for short hydrophobic 
peptide sequences on the carboxyl-terminal end of their target proteins (Fanning and 
Anderson, 1996; Saras and Heldin, 1996). 
 
Four members of the NHERF family, including NHERF1 (NHE-RF, EBP50), 
NHERF2 (E3KARP, SIP-1, TKA-1), NHERF3 (PDZK1, CLAMP, CAP70, DIPHOR-1, 
NaPi-CaP1), and NHERF4 (IKEPP, DIPHOR-2, NaPi-CaP2), have been identified to 
date (Donowitz et al., 2005). All four members have multiple PDZ domains, with an 
additional non-PDZ ERM-binding (EB) region for NHERF1 and NHERF2 but not the 
other two (Murthy et al., 1998; Reczek and Bretscher, 1998; Yun et al., 1998) (FIGURE 
1.5). NHERF1 and NHERF2 also share over 35 common ligands (Shenolikar et al., 2004; 
Weinman et al., 2006); though, in vivo, the two proteins likely serve different functions. 
Their inter- and intra-tissue distributions do not appear to overlap (Fouassier et al., 2001; 
Ingraffea et al., 2002; Wade et al., 2003; Wade et al., 2001); neither is the deficiency of 
NHERF1 compensated by NHERF2 in the renal proximal tubules in mice in vivo 
(Shenolikar et al., 2002; Weinman et al., 2003).  
 
1.5.2  NHERF1 in cells and tissues 
 
Human NHERF1 mRNA is expressed at high levels in polarized epithelia, 
including  liver,  salivary  gland,  kidney,  pancreas,  trachea,  adrenal  glands,   intestines, 
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(PDZK1, CLAMP, CAP70, DIPHOR-1, NaPi-CaP1)
(IKEPP,  DIPHOR-2,  NaPi-CaP2) 
(NHE-RF, EBP50)
 
 
 
FIGURE 1.5 NHERF family members and their domain structures. Human NHERF1, a 
358-residue protein, contains two PDZ (PSD-95/Dlg/ZO-1) domains (red) and a 
carboxyl-terminal ERM-binding region (EB, blue). Three other NHERF family members 
are also shown with multiple PDZ domains; their alternative names are noted in 
parentheses. The domain analysis was performed with NCBI Conserved Domain 
Database (CDD). 
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 prostate, and mammary gland (Ediger et al., 1999). Immunohistochemistry (IHC) studies 
have shown that NHERF1 in many of these tissues is selectively localized at the apical 
membrane of absorptive cells, whereas secretory cells are negative for staining 
(Stemmer-Rachamimov et al., 2001). Immunofluorescence (IF) studies in mouse and rat 
tissues had corroborating results. NHERF1 has been detected in the apical microvilli of 
intestinal (Ingraffea et al., 2002; Reczek et al., 1997) and renal proximal tubule BBM 
(Reczek and Bretscher, 1998; Wade et al., 2001; Waite and Eng, 2002), in mesothelia of 
the stomach (Ingraffea et al., 2002), and at  the  canalicular  (apical)  membranes  of  
both  hepatocytes  and  cholangiocytes (Fouassier et al., 2001; Ingraffea et al., 2002). 
 
1.5.3  NHERF1 in cancer 
 
 The role of NHERF1 in human cancer was first suggested in 2001 (Stemmer-
Rachamimov et al., 2001). This pertained to the observation of a strong positive 
association between NHERF1 expression and estrogen receptor (ER) status in 18 breast 
cancer specimens. As NHERF1 had been earlier shown as an estrogen-inducible gene 
(Ediger et al., 1999), the elevated NHERF1 level in ER-positive tumors was posited as a 
predictable sequalae of estrogenic stimulation. Additional analyses of breast carcinoma 
specimens indicated that the association between NHERF1 expression and ER status 
indeed existed, but indications also were that NHERF1 was more likely accumulated in 
tumors of later than earlier disease stage, with lymph node-positive than -negative status 
and poorer than better prognosis index (Cardone et al., 2007; Song et al., 2007). Possible 
involvements of NHERF1 in breast cancer progression were thereby implicated.  
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  A number of studies have since examined NHERF1 in this and several other 
human neoplasia. Of particular note is a study which reported NHERF1 interaction with 
β-catenin in hepatocellular carcinoma (Shibata et al., 2003). The additional indications 
were that NHERF1 accumulated in the cytoplasm and nucleus in these tumors, and that 
it promoted β-catenin/TCF-dependent transcription. NHERF1, in this context, appeared 
as an oncogenic protein. Two studies, however, have since presented a contrasting view 
that NHERF1 is rather a tumor suppressor protein. In the first of these two studies, 
allelic deletion of the NHERF1 gene locus at 17q25.1 was described at 22-58% 
frequency in breast cancer cells and tissue specimens, with increased tumor 
aggressiveness with loss of heterozygosity (LOH) (Dai et al., 2004). In another study, 
NHERF1 was knocked down in ER-positive T47D and MCF7 breast cancer cells; this 
induced increased cell proliferation both in vivo and in vitro, indicating growth-
suppressive role of NHERF1 in these two breast cancer cells (Pan et al., 2006). The 
current literature thus has conflicting data that are difficult to explain. Reconciliation has 
been offered, in that NHERF1 may have a dual functional role; and that its action as an 
oncogene or else as a tumor suppressor may be dictated by its subcellular localization 
(Georgescu et al., 2008).    
 
1.6  Phenotypes of NHERF1 deficiency in mice 
 
 Our laboratory has generated NHERF1 (-/-) mice, and has found intestinal 
defects as among their main phenotypes. NHERF1, as others have found, is strongly 
expressed at the apical membrane of intestines in these mice (FIGURE 1.6).  The observed  
13 
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FIGURE 1.6 Apical membrane localization of NHERF1 in mouse colon. Confocal IF 
analysis of colon in six week-old C57BL/6J NHERF1 wild-type (+/+) and knockout (-/-) 
female mice is shown. Note strong apical membrane expression of NHERF1 (red). 
Nuclei were marked with ToPro-3 (blue). 
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 defects included overt ultrastructural abnormalities in the intestinal microvilli of BBM 
(FIGURE 1.7); altered composition of intestinal epithelial cells (IECs) (Morales et al., 
2004); and increased length of the intestinal tracts in both male and female mice at 18 
months of age (data not shown). The additional finding was that NHERF1 (-/-) mouse 
embryonic fibroblasts (MEFs) but not their wild-type counterparts displayed anchorage-
independent growth in soft agar colony assay (Kreimann et al., 2007). Taken altogether, 
the inferences from these mouse studies were that NHERF1 may have a role in the 
regulation of apical morphogenesis in the intestine in vivo; that it may regulate the 
growth of IECs; and that it acted as a tumor suppressor, at least in MEFs in vitro. 
 
1.7  Study objective 
 
Given the current literature that implicates the role of NHERF1 in cancer, and the 
results of our NHERF1 (-/-) mouse studies that indicated strong phenotypes in the 
intestine, the main objective of this study was to examine if NHERF1 plays a role in 
human CRC. Specifically, we hypothesized that NHERF1 may act as a tumor suppressor 
in normal human colon and that it may be lost or altered in CRC. The three-part study 
consisted of the following: (1) NHERF1 expression and subcellular localization were 
examined in normal human colonic mucosa, adenoma, and carcinoma specimens 
(Chapter 3.1); (2) NHERF1 expression and subcellular localization were examined in 
CRC tissue microarray (TMA) (Chapter 3.2); and (3) NHERF1 alterations in CRC were 
modeled in cultured 2D and 3D Caco-2 CRC cell systems (Chapter 3.3).  
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FIGURE 1.7 Intestinal microvilli of NHERF1(+/+) and (-/-) mice. Transmission electron 
microscopy of ileum from 5-week-old littermates. Note ordered, rod-like microvilli 
emerging from a structured terminal web region (bracket) in EBP50(+/+), contrasting 
with the EBP50(-/-) disorganized microvilli and thick terminal web. x12,000. Reprinted 
with permission from Morales et al., Proc Natl Acad Sci USA, 2004; 101(51): 17705-
17710. Copyright © 2004 National Academy of Sciences, U.S.A.    
 
 
 
  
  
 
CHAPTER 2 
 
MATERIAL AND METHODS 
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 2.1  CRC resection specimens and tissue microarray 
 
Eleven paraffin-embedded surgical CRC resection specimens and seven 
additional liquid nitrogen-frozen specimens were obtained from the Institutional Tumor 
Bank at M. D. Anderson Cancer Center. Surgeries for all cases had been performed in a 
15-year period between 1992 and 2007, with no patient receiving prior treatment. All 
paraffin-embedded specimens contained areas of normal mucosa, adjacent adenoma, and 
carcinoma on the same slide. Frozen specimens had pathologist-annotated vials of 
normal mucosa, deep-tumor, and tumor-edge as normal, carcinoma, and adenoma, 
respectively. The TARP (Tissue Array Research Program) colon and lung (T-CL-1) 
TMA was obtained from the U.S. National Cancer Institute-Center for Cancer Research 
(NIH-CCR) (http://ccr.cancer.gov/tech_initiatives/tarp/).  This array by design contained 
89 CRC specimens with 0.6-mm cores space at 0.8 mm. Approximately three-quarters of 
the samples (74-83% of 89 samples) had actually usable tissues.  
 
2.2  Tissue staining 
 
2.2.1  H&E staining 
 
Paraffin-embedded sections were serially treated in xylene (10 min x3), graded 
ethanol: 100% (10 min x2), 95% (10 min x1), 70% (10 min x1), and ddH2O (10 min x1); 
and were stained with hematoxylin (Fisher Scientific, #23-245-651) for 3 min. After a 
rinse in ddH2O for 2 min, the sections were blued in tap water for 5 min; de-stained in 
0.2% acid alcohol (70% ethanol with 0.2% HCl) for 30 sec; and rinsed in ddH2O for 2 
min. The sections were then stained with eosin (Fisher Scientific, #323-314-631) for 30 
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 sec; rinsed in ddH2O for 2 min; and dehydrated in graded ethanol: 95% (2 min x1) and 
100% (2 min x1).  The sections were cleared in xylene; and Permount (Fisher Scientific, 
#SP15-100) was used to mount the slides. 
 
2.2.2  Immunofluorescence (IF) 
 
Sections were deparaffinated and hydrated as above (see section 2.2.1); and heat-
induced antigen retrieval was performed in a vegetable steamer for 20 min in 1/10x 
Target Retrieval Solution (Dako, #S1699). All sections were cooled for 10 min at room 
temperature; then rinsed in ddH2O for 5 min three times. Blocking was performed with 
20-50% donkey serum (Sigma, #G9023) in PBS for 30 min at room temperature. The 
primary antibodies (listed in TABLE 2.2) were applied in PBS in a humidified chamber at 
4°C overnight. Next day, the sections were washed in PBS for 5 min three times; and 
one or both of the secondary antibodies Alexa Fluor 488 donkey anti-rabbit IgG and 
Alexa Fluor 555 donkey anti-mouse IgG (Molecular Probes, #A21206 and #A31570, 
respectively) was applied at 1:500 for 45 min, covered with aluminum foil. After three 
5-min washes of the sections in PBS, ToPro-3 iodide (Molecular Probes, #T3605) was 
applied at 1:2000 in PBS for 20 min.  After two final 5-min washes in PBS, Slowfade 
Gold antifade reagent (Invitrogen, #S36936) was applied to mount the slides.  
 
2.2.3  Immunohistochemistry (IHC) 
 
Manual staining. Sections were deparaffinated and hydrated as above (see  
section 2.2.1); and endogenous hydrogen peroxidase activity was quenched by treatment  
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Antibody Use Product Dilution 
NHERF1 IF, IHC Affinity BioReagents, #PA1-090 1:300 
β-catenin IF, IHC BD Biosciences, #C19220 1:300 
E-cadherin IHC BD Biosciences, #C20820 1:100 
Cytokeratin IHC Sigma, #C1801 1:100 
 
 
TABLE 2.1 Primary antibodies used for manual IF/IHC tissue staining.  
20 
 of the sections in 3% hydrogen peroxide in methanol for 10 min at room temperature. 
After three 2-min washes of the sections in PBS, heat-induced antigen retrieval was 
performed for 20 min as described above (see section 2.2.2). Blocking was performed 
using 1A and 1B solutions of the Histomouse-Max kit (Zymed Laboratories, #87-9551) 
for 30 min and 10 min at room temperature, respectively. The primary antibodies (listed 
in TABLE 2.2) were then applied in PBS at 4°C overnight. Next day, the sections were 
washed in PBS for 2 min three times; and 3,3’-diaminobenzidine (DAB) staining and 
nuclear hematoxylin counterstaining were performed per manufacturer’s instructions of 
the Histomouse-Max kit. The sections were dehydrated in graded ethanol: 70% (5 min 
x1), 95% (5 min x1), 100% (5 min x2); cleared in xylene; and mounted using 
Histomount of the kit.  
 
Automated staining. Five sections of CRC specimens were submitted to an 
American Society of Clinical Pathology/Texas Society of Histotechnology 
(ASCP/TSH)-certified Clinical Histology Laboratory, on-site at M. D. Anderson Cancer 
Center. The following primary antibodies: CD3, CD4, CD8, CD20, CD68 (listed in 
TABLE 2.3) were used to perform IHC staining in an automated Leica Bond-I system. 
 
2.3  Image acquisition 
 
2.3.1  IF images 
 
Multi-channel IF images were acquired using the Zeiss LSM 510 confocal laser 
scanning microscope, with excitation laser lines of 488 nm (green), 543 nm (red), and 
633  nm  (far  red);  and  differential  interference  contrast  (DIC).   For  all  images,  the 
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Antibody Marker Product Dilution 
CD3 T cell Dako, #A0452 1:100 
CD4 Helper T cell Novacastra, #NCL-L-368 1:80 
CD8 Cytotoxic T cell Dako, #MS-457-S 1:20 
CD20 B cell Dako, #M0755 1:1400 
CD68 Macrophage Dako, #M0814 1:500 
 
 
TABLE 2.2 Primary antibodies used for automated IHC tissue staining.  
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 40x/1.30 NA (numerical aperture) objective lens with oil immersion was used. All 
images were processed with the LSM 510 software, version 4.2. 
 
2.3.2  Brightfield images 
 
H&E and IHC images were acquired using the Nikon 80i upright microscope and 
Nikon DS-U2/L2 USB camera, with the 4x/0.2, 10x/0.45, an 20x/0.75 NA dry objective 
lenses. All images were processed with the NIS Elements AR software, version 3.1.  
 
2.4  Image analyses 
 
2.4.1 IF/IHC signal intensity analysis 
 
Quantitative signal intensity analysis of selected IF/IHC images was performed 
in an 8-bit (28 = 256) gray densitometry scale from 0 (black) to 255 (white). The sample 
region of interest was circled using the NIH Image J software, version 1.34s; mean 
signal intensity was measured; and signal intensity score, x, was computed as x = [255 - 
(mean intensity reading)].  
 
 2.4.2  Nuclear localization analysis 
 
Nuclear localization analysis of the triple IF-stained TMA samples was 
performed using co-localization analysis mode of the Bitplane AG Imaris x64 software, 
version 6.3.0. Data outputs were tallied as %Alexa 488 (green)/ToPro-3 co-localized 
voxels (nuclear green); %Alexa 568 (red)/ToPro-3 co-localized voxels (nuclear red); 
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 and %Alexa 488/Alexa 568/ToPro-3 co-localized voxels (nuclear green/red co-
localization). 
 
2.5  Immunoblot analysis of frozen tissues 
 
All tissues were stored at -80°C until use. The whole tissue lysates were prepared 
by homogenizing the samples with a motorized pestle (Kontes, #K749540-0000), in the 
same 1% Triton X-100 buffer and protease inhibitor cocktails as that used for whole cell 
lysis (see section 2.15). Protein concentration was measured and immunoblotting was 
performed as described (see sections 2.15 and 2.16). 
 
2.6  Cell culture 
 
The Caco-2 colon adenocarcinoma cells (a gift from Dr. Alan Hall, Memorial 
Sloan-Kettering Cancer Center, NY) were grown in a 50/50 mixture of Dulbecco 
modified Eagle’s medium/Ham’s F-12 nutrients (DMEM/F-12) supplemented with 10% 
fetal calf serum (FCS) (Hyclone, #SH30910-03) and 1/100x antibiotic-antimycotic 
(Invitrogen, #15240-062). The 293T human embryonic kidney cells were grown in 
DMEM, also supplemented with 10% FCS and 1/100x antibiotic-antimyotic. 
 
2.7  Plasmids 
 
NHERF1 shRNA#1 (ACCCCATCCTAGACTTCAA) and shRNA#4 
(GGGAAACT GACGAGTTCGG) were cloned in the pSIREN-RetroQ retroviral vector 
(puromycin selection), as previously described (Kreimann et al., 2007). Wild-type 
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 NHERF1 (358 residues) had been previously cloned in  the  pCXb  vector  (Kreimann et 
al., 2007).  The myristoylation signal of v-Src, MGSSKSKPKDPSQR, and the nuclear 
localization signal (NLS) of SV40 T antigen, PKKKRKV, were added N-terminally to 
the wild-type NHERF1 in the pCXb vector, generating Myr-NHERF1 and NLS-
NHERF1, respectively. The Myr signal was also added to the NHERF1 PDZ1-2 
construct that lacks the terminal EB region. The retroviral constructs encoding AKT, 
PTEN, and ΔPDZ (former PTEN-401, (Georgescu et al., 1999a)) were obtained by 
inserting in the pCXn vector (G418 selection) the cDNAs in frame with HA or Myc tags, 
respectively. 
 
2.8  Transfection and retroviral infection 
 
The 293T cells in 6-cm dishes (2.5 x 106 cells/dish, 16h post-plating) were co-
transfected with 1 μg of retroviral construct and 1 μg of pCL-Ampho plasmid, with 6 μL 
of FuGENE (Roche #04-981- 057-001) in serum-free DMEM (Georgescu et al., 1999a). 
At 48h post-transfection, the medium containing retroviral particles was added on Caco-
2 cells using a 0.45 μm-filter syringe (Corning, #09-754-21), and 8 μg/mL of Polybrene 
(Sigma, #28728-55-4) co-treatment. At 6h post-infection, the viral supernatant was 
removed from the Caco-2 cells and replaced with 10% FCS DMEM/F-12. At 48h post-
infection, selection of the cells were begun with the growth medium containing 1 μg/mL 
of puromycin (Sigma, #P8833), 2.5 μg/mL of blasticidin (Invitrogen, #R210-01), and/or 
1 μg/mL of G418 (Invitrogen, #11811-023). Selection lasted for approximately 5 days or 
until satisfactory expression of the retroviral constructs was obtained.  
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 2.9  Epithelial morphogenesis assay 
 
The single suspensions of Caco-2 cells were embedded in 40% growth factor-
reduced Matrigel (BD Biosciences, #354230)/growth medium (v/v) with 20 mM HEPES 
(pH 7.4) (Invitrogen, #15630), to produce 3D cysts in 8-well chamber slides (Fischer 
Scientific, #12-565-8), as previously described (Jaffe et al., 2008). The cell-matrix 
mixture was overlayed with 400 μL of Caco-2 growth medium, and re-fed on day 4 post-
embedding. Prior to IF on day 2, 3, 4, or 8, cells were washed with PBS three times, 
fixed with 4% paraformaldehyde (PFA) for 30 min, and washed three times with 1/10x 
IF wash buffer containing 130 mM NaCl, 13 mM Na2HPO4 (Sigma, #S9390), 3.5 mM 
Na2H2PO4 (Sigma, #S9368), 0.5% NaN3, 1% bovine serum albumin (BSA) (Sigma, 
#A7888), 2% Triton X-100, and 0.5% Tween-20. Blocking was performed in 1% BSA 
in 1/10x IF wash buffer for 30 min. The primary antibodies (listed in TABLE 2.4) were 
applied in this blocking buffer overnight at 4°C. Next day, cells were washed with 1/10x 
IF wash buffer three times for 10 min; and the secondary antibodies Alexa Fluor 568 
goat anti-rabbit IgG, Alexa Fluor 488 goat anti-mouse IgG, and/or rhodamine-phalloidin 
(Molecular Probes, #A11011, #A11001, and #R145, respectively) applied at 1:200 for 
45 min at room temperature, covered with aluminum foil, and with ToPro-3 iodide 
(Molecular Probes, #T3605) co-incubation at 1:2000. Cells were washed again with 
1/10x IF wash buffer for 10 min three times, then with PBS for 5 min three times. The 
Slowfade Gold antifade reagent (Invitrogen, #P36934) was used to mount the slides. 
Images were acquired with the Zeiss LSM 510 confocal microscope, using 63 x/1.40 NA 
objectives with oil immersion; and processed with the LSM 510 software, version 4.2. 
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Antibody Marker Product Dilution 
NHERF1 apical Affinity BioReagents, #PA1-090 1:500 
E-cadherin basolateral BD Biosciences, #C20820 1:250 
Ezrin apical BD Biosciences, #610602 1:250 
GM130 GA BD Biosciences, #G65120 1:250 
β-catenin basolateral Sigma, #C2206 1:500 
Laminin BM Sigma, #L9393 1:500 
ZO-1 TJ Zymed Laboratories, #61-7300 1:250 
aPKC (C-20) apical Santa Cruz Biotechnology, #sc-216 1:200 
PTEN (A2B1) apical Santa Cruz Biotechnology, #sc-7974 1:200 
Myc (9E10) n/a Santa Cruz Biotechnology, #sc-40 1:50 
HA n/a Boehringer Mannheim, #1-583-816 1:200 
P-HH3-S10 mitosis Upstate Biotechnology, #06-570 1:500 
 
 
TABLE 2.3 Primary antibodies used for epithelial morphogenesis assay. GA, Golgi 
apparatus; BM, basement membrane; TJ, tight junction. 
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 2.10  Cell morphology assay 
 
Cell morphology was assessed by plating 5x105 cells in duplicate in 2% FCS 
DMEM in 6-well dishes, and cultured for 10 days at 37°C. On Day 10, cells were 
washed with PBS twice; fixed with 10% acetic acid for 20 min;  and  stained with  0.1%  
 crystal violet solution in methanol for 20 min. Phase-contrast images of the crystal-
violet stained cells were obtained using 5x/0.12 and 20x/0.50 NA objectives of the Zeiss 
Axiovert 200 inverted microscope.  
 
2.11  Migration assay 
 
Cell migration was assessed by scratching a confluent cell monolayer in 
duplicate with sterile 2-200μL tip in serum-free DMEM. The scratch site was pen-
marked and monitored once daily for closure: at 0, 24, and 48h. Phase-contrast images 
were obtained each day, using 10x/0.25 objective of the Zeiss Axiovert 200 inverted 
microscope. The widths of the scratch site were measured using Image J (NIH, version 
1.34s). The distance of cell migration was computed as: (width of scratch site at 0h) – 
(width of scratch site at 48h).  
 
2.12  Invasion assay 
 
Cell invasion was assessed by suspending 1x106 cells in duplicate in 250 μL of 
serum-free DMEM, in transwells with 8-μm pore size polycarbonate filters (Corning 
#07-200-150) pre-coated with 100 μL of 0.7 mg/mL Matrigel (BD Biosciences 
#354234). The wells below the polycarbonate filters were filled with 750 μL of 10% 
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 FCS DMEM to obtain a chemogradient across the transwell. At 48h post-plating, cells 
on the upper surface of the filter were removed with a cotton swab. Migratory cells 
remaining on the lower surface of the filter were fixed and stained with the HEMA3 
stain set (Fisher, #22-122-911). Images were acquired using 5x/0.12 and 10x/0.25 NA 
objectives of the Zeiss Axiovert 200 inverted microscope. The number of cells in the 
fields was counted using Image J software (NIH, version 1.34s).   
 
2.13  Gelatin zymography 
 
To analyze the activities of secreted MMPs, 2.5x105 cells were plated in 10% 
FCS DMEM/F-12 in 12-well dishes. After overnight incubation to allow cell attachment 
to the dishes, growth medium was removed and replaced with serum-free DMEM. At 
24h into serum starvation, the conditioned medium was collected and spun at 10,000 g 
for 5 min. The cell-free supernatant, normalized to cell numbers, was mixed with 1/4x 
sample buffer containing 0.25 M Tris (pH 6.8), 20% glycerol, 4% SDS, and 0.02% 
bromophenol blue; and loaded without boiling on 12% polyacrylamide gels co-
polymerized with 1 mg/mL gelatin (Sigma, #G6650). Following separation of the 
proteins by non-denaturing electrophoresis, the gel was washed twice for 30 min in wash 
buffer containing 2.5% Triton X-100, 50 mM Tris (pH 7.5), 5 mM CaCl2, 1 μM ZnCl2, 
and 0.02% NaN3.  It was then equilibrated for 30 min at room temperature in the same 
buffer except with 1% Triton X-100, thereafter incubated in this buffer for 48h at 37°C.  
Coomassie Blue (Bio-Rad, #161-0436) was used to stain the gel for 30 min, and the 
white bands of gelatin-cleared areas were sought in the dark blue background.   
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 2.14  Proliferation assay 
 
1x104 cells were plated in triplicate in 2% FCS DMEM/F-12 in 24-well dishes.  
The increments in cell number were counted at 24h post-plating (D1) and subsequently 
every other 3 days up to D13, using Beckman-Coulter Vi-Cell analyzer. 
 
2.15  Whole cell lysis 
 
Cells removed from the growth medium were washed with PBS; scraped; and 
lysed in ice-cold cell lysis buffer containing 1% Triton X-100, 50 mM HEPES (pH 7.5), 
100 mM NaCl, 10 mM EDTA, 10% glycerol, and protease inhibitor cocktails: 1 mM 
sodium orthovanadate (pH 10.0) (Sigma, S-6508), 0.1 mM sodium molybdate (Sigma, 
#S-6646), 1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma, P-7626), and 1% 
aprotinin (Sigma, #A-6279) (Georgescu et al., 1999b). After 15 min of incubation on ice, 
the samples were spun for 15 min at 16,000 g; and the cleared lysates were collected in 
new tubes. Protein concentrations of the lysates were then measured, using BSA 
standards (range: 0.5-20 μg/mL), and following manufacturer’s instructions of the Micro 
BCA Protein Assay kit (Thermo Scientific, #PI-23223 and #PI-23224).  
 
2.16  Immunoblotting 
 
Protein samples were mixed with 1/6x sample buffer containing 125 mM Tris 
(pH 6.8), 10% SDS, 2.5% glycerol, 1.25% 2-mercaptoethanol, and 0.2% bromophenol 
blue. These were then boiled at 95°C for 5 min; and loaded on 8, 10, or 12% SDS-
polyacromide gel. The proteins were separated by gel electrophoresis in 1x running 
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 buffer containing 25 mM Tris, 200 mM glycine, and 0.1% SDS (w/v). Prestained Rec 
Protein ladder (Fisher BioReagents, #BP3603) was run with each gel. The proteins were 
then transferred to the Immobilon-P membrane (Millipore, #IPVH00010) using the Bio-
Rad Trans-Blot SD Semi-Dry Trans Cell system at 5V for 2h, in 1x transfer buffer 
containing 25 mM Tris, 200 mM glycine, 20% methanol (v/v), and 0.375% SDS. 
Blocking of the membrane was performed with 3% BSA in 1x TBST buffer containing 
50 mM Tris (pH 7.5), 150 mM NaCl, and 0.1% Tween-20 for 30 min. The primary 
antibodies (listed in TABLE 2.5), were applied in this blocking buffer for overnight at 
4°C. Next day, the membrane was washed with 1x TBST for 5 min three times. The 
horseradish peroxidase (HRP)-conjugated mouse or rabbit secondary antibody (Jackson 
ImmunoResearch Laboratories, #115-035-071 and #711-036-152, respectively) was then 
applied at 1:40,000-1:10,000 for 45 min in 1x TBST; and the membrane was washed in 
1x TBST for 5 min three times. The Western-Lightning Chemiluminesence Reagent 
(Perkin-Elmer, #NEL105001EA) was applied and the protein bands were visualized on 
autoradiography films.   
 
2.17  Immunofluorescence of cells (IF-C) in 2D monolayer culture 
 
The cells were grown to confluency in Permanox plastic 4-well chamber slides 
(Thermo Scientific, #12-565-2). After removal of the growth medium and a wash in   
PBS, the cells were fixed with 4% PFA for 20 min at room temperature. Next, the cells 
were washed with PBS three times; then permiabilized with 0.1% Triton X-100 in PBS 
for 10 min. After another three washes in  PBS,  few drops of  Image-IT  FX Signal  
Enhancer  (Invitrogen, #I36933) were added for 30 min at  room  temperature.  Blocking 
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Antibody MW, kDa Product Dilution 
NHERF1 50-53 BD Biosciences, #611160 1:1000 
E-cadherin 120 BD Biosciences, #610181 1:1000 
Fibronectin 240 BD Biosciences, #610077 1:1000 
β-catenin 92 BD Biosciences, #610153 1:1000 
GAPDH (0411) 37 Santa Cruz Biotechnology, #sc-47724 1:5000 
Akt 60 Cell Signaling, #9272 1:1000 
PTEN (A2B1) 55 Santa Cruz Biotechnology, #sc-7974 1:1000 
Myc n/a Invitrogen, #R950-25 1:5000 
HA n/a Boehringer Mannheim, #1-583-816 1:2000 
 
 
TABLE 2.4 Primary antibodies used for immunoblotting. 
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 was performed in 1% BSA in PBS for 30 min; and the primary antibodies (listed in 
TABLE 2.6), were applied in PBS for 2h at room temperature. The cells were washed 
with PBS for 10 min three times; and the secondary antibodies Alexa Fluor 568 goat 
anti-rabbit IgG and Alexa Fluor 488 goat anti-mouse IgG (Molecular Probes, #A11011 
and #A11001, respectively) were applied at 1:500, with ToPro-3 iodide (Molecular 
Probes, #T3605) at 1:2000, for 1h. After final three washes of the cells in PBS for 10 
min each time, the slides were mounted with Slowfade Gold antifade reagent (Invitrogen, 
#P36934). Images were acquired with the Zeiss LSM 510 confocal microscope, using 
63x/1.40 NA objectives with oil immersion; and processed with the LSM 510 software, 
version 4.2. 
 
2.18  Statistical analysis 
 
All numerical data were examined for normality of distribution. Parametric or 
non-parametric methods of one- or two-way analysis of variance (ANOVA) and t-test 
were used, as appropriate, to analyze the differences between groups or groups by day. 
Tukey’s test was used for multiple comparisons. A 3x3 contingency table of categorical 
data from CRC cases was analyzed by Fisher’s exact test. For all tests, statistical 
significance was considered for P <0.05. Unless otherwise indicated, data are presented 
as mean ± standard error of the mean (SEM).  
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Antibody Marker Product Dilution 
NHERF1 apical Affinity BioReagents, #PA1-090 1:500 
E-cadherin basolateral BD Biosciences, #C20820 1:250 
β-catenin basolateral Sigma, #C2206 1:500 
 
 
TABLE 2.5 Primary antibodies used for IF-C. 
 
 
 
  
 
CHAPTER 3 
 
RESULTS 
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 3.1  CRC case study 
 
3.1.1  Patient demographics and H&E analyses 
 
Patient demographic data for the 11 CRC cases are presented in TABLE 3.1. All 
patients were in their 50’s, 60’s or 70’s, with comparable numbers of men and women. 
The most common primary tumor site was sigmoidal colon, with most common disease 
diagnosis being UICC (International Union Against Cancer) T2N0M0, or AJCC 
(American Joint Committee on Cancer) Stage I, CRC. Post-diagnosis median survival 
for this group of patients was 12 years (FIGURE 3.1). For all cases, H&E-stained slides 
were reviewed by a gastrointestinal pathologist at M. D. Anderson Cancer Center (Dr. 
Stanley Hamilton, Department of Pathology). On the basis of histology, three areas on 
the slides: normal mucosa, adenoma, and carcinoma, were defined for each case. Two of 
these cases: Patient 8 and 10, are presented in FIGURE 3.2.  
 
3.1.2  IF and IHC analyses 
 
3.1.2.1  Altered NHERF1 expression in adenoma and carcinoma   
 
For all 11 cases (100%), NHERF1 localization as assessed by confocal IF and/or 
IHC was at the apical membrane in normal mucosa. In adjacent adenoma and carcinoma, 
however, this apical membrane staining was lost and NHERF1 was very low or not 
detectable in 10 of 11 (91%) of adenoma and 6 of 11 (55%) carcinoma cases. In the 
remaining 1 of 11 (9%) of adenoma and 5 of 11 (45%) carcinoma areas, NHERF1 was 
strongly re-expressed in the cytoplasm.  A graphical summary for  these area  categorical
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 All patients (n=11) Patient 8 Patient 10 
Sex, M:F 4:7 M F 
Age, y (range) 63.0 ± 3.3 (50-79) 79 53 
    
Primary tumor site,                
C:A:T:D:S:R 
2:2:1:0:4:2 S S 
    
TNM Stage, T1:T2:T3:T4 2:6:3:0 T2 T3 
AJCC Stage, I:II:III:IV 8:1:1:1 I III 
 
 
TABLE 3.1 Demographic characteristics of patients in CRC case study. n=11. Primary 
tumor sites are: C, cecum; A, ascending colon; T, transverse colon; D, descending colon; 
S, sigmoid colon; R, rectum. T scores only of the TNM staging system are shown. Patient 
8 and 10, respectively, represent the cases depicted in FIGURE 3.4 and FIGURE 3.5. 
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FIGURE 3.1 Post-CRC diagnosis survival status of patients in CRC case study. Median 
survival was 12 years. n=11. Disease-specificity of the deaths is unknown. 
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Patient 8
Patient 10
  
 
 
 
FIGURE 3.2 Normal, adenoma, and carcinoma areas in CRC resection specimens. H&E 
sections of two representative cases (Patient 8 and 10) are shown. Note the areas of 
normal colonic mucosa (blue lining), adjacent adenoma (green lining), and invasive 
carcinoma (red lining) for each case. Boxes indicate selected regions of these three areas 
for which IF and IHC analyses are presented in FIGURE 3.4 (Patient 8) and FIGURE 3.5 
(Patient 10). 
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 comparisons is presented in FIGURE 3.3. The observed differences in NHERF1 staining 
pattern were statistically significant (χ2=38.5, d.f.=4; P < 0.001). The two split patterns 
of NHERF1 expressions in carcinomas –the first pattern  in which  there is  low/ no 
expression of NHERF1, and second pattern in which it is re-expressed in cytoplasm– are 
represented by two cases (Patient 8 and 10) in FIGURE 3.4 and FIGURE 3.5, respectively. 
Quantitative analyses of these IF data are presented in FIGURE 3.6 and FIGURE 3.7, 
respectively. 
 
3.1.2.2  Nuclear NHERF1 at the invasive front of carcinoma  
 
In seeking tumor cells deeper in the mucosa, a small cluster of cells displaying 
NHERF1 in the nucleus was found. These cells appeared to be moving away from a 
nearby tumor mass, and were larger than, and shaped differently from, NHERF1-
negative stromal cells in the surrounding neighborhood (FIGURE 3.8). While this was the 
only area in this section where nuclear NHERF1 could be detected, re-inspection of 
other 10 IHC sections showed that, indeed, nuclear species of NHERF1 are present in 
many other protruding areas or isolated masses of invasive tumors (FIGURE 3.9). 
 
3.1.2.3  NHERF1-positive T lymphocytes   
 
Unexpectedly, we also found some strongly NHERF1-positive non-epithelial 
cells that infiltrated some areas of normal colonic mucosa (FIGURE 3.10). As the IHC 
analyses of  serial sections  showed, these  were  likely  CD3  (T  lymphocyte)  and  CD4 
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FIGURE 3.3 Area comparisons of NHERF1 intracellular distribution. A graphical 
summary of IF and/or IHC staining results is shown. n=11. N, normal mucosa; A, 
adenoma; C, carcinoma. PM, plasma membrane. d.f. = degree of freedom. †P < 0.001. 
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FIGURE 3.4 Loss of NHERF1 expression in carcinoma. IF and IHC analyses with 
NHERF1 antibody show loss of apical membrane NHERF1 in normal mucosa (left 
panels) from both adenoma (middle panels) and carcinoma (right panels) areas. A 
representative case (Patient 8) is shown. Arrowheads in middle panels indicate normal 
mucosa. Cell nuclei were marked with ToPro-3 (blue for IF) and hematoxylin (blue for 
IHC). 
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FIGURE 3.5 Cytoplasmic overexpression of NHERF1 in carcinoma. IF and IHC analyses 
with NHERF1 antibody show strong cytoplasmic expression of NHERF1 in carcinoma 
(right panels). The corresponding NHERF1 staining in normal mucosa is apically 
localized (left panels), with loss in adenoma (middle panel) as seen in FIGURE 3.4. A 
representative case (Patient 10) is shown. Cell nuclei were marked with ToPro-3 (blue for 
IF)- and hematoxylin (blue for IHC).   
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FIGURE 3.6 Quantitative analysis of IF data for NHERF1 loss. Densitometric analysis of 
membrane NHERF1 intensity is shown. N, normal mucosa; A, adenoma; C, carcinoma. 
Data are means ± SEM of the triplicate measurements for Patient 8. ***P < 0.001 vs. N. 
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FIGURE 3.7 Quantitative analysis of IF data for cytoplasmic NHERF1 overexpression. 
Densitometric analysis of cytoplasmic NHERF1 intensity is shown. N, normal mucosa; 
A, adenoma; C, carcinoma. Data are means ± SEM of the triplicate measurements for 
Patient 10. *P < 0.05 vs. N. 
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FIGURE 3.8 Nuclear NHERF1 at the leading edges of invasive tumor cells. IHC analysis 
with NHERF1 antibody as in FIGURE 3.5 (Patient 10) shows nuclear expression of 
NHERF1 in small groups of tumor cells at the leading edge of invasion (arrowheads in 
inset). Cell nuclei were marked with hematoxylin (blue). 
 
 
46 
  
 
 
 
 
Case 4
Case 9 Case 11
Case 5
 
 
 
 
FIGURE 3.9 More nuclear NHERF1 at the leading edges of invasive tumor cells. IHC 
analysis of additional CRC cases as in FIGURE 3.8 shows nuclear expression of NHERF1 
in many protruding areas or isolated masses of invasive carcinomas (arrowheads). Cell 
nuclei were marked with hematoxylin (blue).  
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FIGURE 3.10 NHERF1-positive immune cells infiltrate the colonic mucosa. Confocal IF 
analysis of NHERF1 (green)-stained section shows massive infiltration of NHERF1-
positive non-epithelial cells in some areas of colonic mucosa. β-catenin (red) co-stained. 
Cell nuclei were marked with ToPro-3 (blue). 
 
 
 
 
 
 
 
 
 
 
 
48 
 (helper T lymphocyte)-positive T lymphocytes that stained, as did NHERF1, most 
intensely  in  the cortex of lymphoid nodule and in intraepithelial regions  (FIGURE 3.11). 
Other markers, such as CD20 (B lymphocyte), CD68 (macrophage), and CD8 (cytotoxic 
T lymphocyte) stained more prominently in the germinal center or else did not stain in 
these areas.  
 
3.1.3  Immunoblot analysis 
 
Supplemental immunoblot analysis of liquid nitrogen-frozen CRC specimens 
was performed with seven additional cases. In five of these cases (cases 12-16) (71%), 
NHERF1 expression was notably decreased in both adenoma and carcinoma as 
compared with normal mucosa. In the remaining two cases (cases 17-18) (29%), 
NHERF1 was detected in both adenoma and carcinoma but as the lower molecular 
weight form (FIGURE 3.12). All lanes of samples showed multiple molecular weight 
forms of NHERF1, with the highest form in the normal tissue, and the lower forms in 
both adenoma and carcinoma. The low molecular weight form of NHERF1, as compared 
to the apical membrane associated higher molecular weight form, is likely 
hypophosphorylated and localized in the cytoplasm (Saotome et al., 2004). We noted 
truncated oncogenic form of β-catenin in adenoma and carcinoma in two of seven cases 
(cases 14 and 16).  
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FIGURE 3.11 Characterization of NHERF1-positive immune cells. (A) A lymphoid nodule 
with NHERF1-positive cells is shown in the cortical area (arrowhead). Serial IHC analysis 
with immune cell markers showed CD3 (T lymphocytes) and CD4 (helper T lymphocytes) 
as the best matches to NHERF1. Also used were: CD20 (B lymphocytes), CD68 
(macrophages), and CD8 (cytotoxic T lymphocytes). (B) Intraepithelial region showing 
NHERF1-positive cells. The best match to NHERF1 was again indicated with CD3 and 
CD4.  
51 
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FIGURE 3.12 Low molecular weight form of NHERF1 in carcinoma. Immunoblot 
analysis of whole tissue lysates is shown. Proteins were loaded at 20 μg per lane. N, 
normal; A, adenoma; C, carcinoma. The lines mark the high and low molecular weight 
forms of NHERF1 and the star the lower form, likely representing hypo-phosphorylated 
and cytoplasmically localized NHERF1. Also note truncated β-catenin mutants in Cases 
14 and 16 (arrowheads). GAPDH was used as a loading control. 
 
 
 
 
 3.2  CRC tissue microarray study 
 
3.2.1  IHC analysis 
 
To examine NHERF1 expression in a larger number of CRC samples, we 
obtained T-CL-1-TARP colon TMA to repeat the IHC analysis with NHERF1 antibody. 
A scanned section of this IHC-stained TMA is presented in FIGURE 3.13. As the 
indication was clear that individual TMA samples varied in their IHC reactivity, 
densitometric quantification was obtained for each of these samples.  
 
3.2.1.1  Analysis by three groups of tumor grade 
 
The colon section of this TMA had limited patient data: gender (51/89 of 
samples), age (51/89 of samples), and tumor grade (31/89 of samples, not matched to 
gender or age data). Although initial efforts were directed at examining these limited 
data for possible association with densitometric values of IHC-NHERF1 intensity, all 
results lacked sufficient power to not reject the null hypothesis, due to unmatched 
datasets, less usable tissues, and larger data variability (TABLE 3.2). An alternative data 
reduction approach was therefore taken, as below.  
 
3.2.1.2  Analysis by four groups of IHC-NHERF1 intensity scores 
 
The histogram showing the distribution of IHC-NHERF1 intensity scores for the 
TMA samples is presented in FIGURE 3.14. The IHC-NHERF1 intensity scores ranged 
from 46 to 142 in an 8-bit scale of  0  to  255,  with  a  mean  (⎯x)  of  99.0  and  standard 
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FIGURE 3.13 IHC-stained CRC TMA section with NHERF1 antibody. A scanned 
section of the TMA samples is shown. Note marked inter-sample differences in IHC 
reactivity to NHERF1 antibody. Cell nuclei were marked with hematoxylin (blue).  
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  Well-
differentiated 
Moderately 
differentiated 
Poorly 
differentiated 
Sex, M:F Data missing Data missing Data missing Data missing 
Age, y Data missing  
 
Data missing Data missing 
 
Data missing  
n 
NHERF1 score      
24 
92.8 ± 4.7 
6 
86.3 ± 12.0 
15 
96.3 ± 5.8 
3 
88.2 ± 6.9 
 
TABLE 3.2 IHC-NHERF1 intensity scores of TMA samples by tumor grade. n=24 (seven 
less usable data). Descriptive statistics could not be computed for patient sex and age, as 
data points for these variables were unmatched to tumor grade. The resultant small 
sample size and larger data variability. 
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FIGURE 3.14 Distribution of NHERF1 intensity scores in CRC TMA samples. n=70. 
Defined score range is 0 (white) to 255 (black). Groups were assigned to each TMA 
sample according to their IHC intensity scores. Cut-off values for the groups were 
derived from the descriptive statistics mean (⎯x) and SD (σ). 
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 deviation (σ) of 22.0. On the basis of these descriptive statistics, four groups were 
defined in equal decrements of IHC-NHERF1 intensity scores: Group I (scores >121), 
Group II (scores 100-121), Group III (scores 78-99), and Group IV (scores ≤77). The 
mean differences in NHERF1 intensity scores, as defined, for Group I and II (130.8 ± 
2.2 vs. 109.0 ± 1.1, P <0.001), II and III (109.0 ± 1.1 vs. 89.3 ± 1.5, P < 0.001), and III 
and IV (89.3 ± 1.5 vs. 67.2 ± 3.3, P < 0.001), are presented in FIGURES 3.15. The four 
groups of TMA samples differed in several parameters. Namely, there was a decreasing 
trend for both epithelial tissue content and tumor differentiation between Group I, II, III, 
and IV. There was also a converse increasing tendency in the surrounding stromal 
content, and a shifting tendency for NHERF1 subcellular localization in which 
predominant cytoplasmic localization of NHERF1 in Group I became increasingly 
nuclear toward Group IV (FIGURE 3.16). The re-analysis of TMA sample distribution in 
this grouping scheme is presented in TABLE 3.2. 
 
3.2.1.3  Serial analyses with β-catenin, E-cadherin, and cytokeratin 
 
Serial analyses of TMA sections with three epithelial markers: β-catenin, E-
cadherin, and cytokeratin were then performed. Although none of these epithelial 
markers showed significant differences in their IHC intensity scores between Group I 
and II (β-catenin, 125.0 ± 10.6 vs. 113.6 ± 3.8; E-cadherin, 109.6 ± 8.7 vs. 110.4 ± 4.4; 
cytokeratin, 91.3 ± 5.4 vs. 86.0 ± 2.2; all P= NS), they did all indicate stepwise 
decreases from Group II to III (β-catenin, 113.6 ± 3.8 vs. 84.6 ± 5.6; E-cadherin, 110.4 ± 
4.4 vs. 79.4 ± 4.6; cytokeratin, 86.0 ± 2.2 vs. 71.4 ± 3.8; all P < 0.001) and from Group 
III  to  IV  (β-catenin,  84.6 ± 5.6  vs. 52.9 ± 3.2;  E-cadherin,  79.4 ± 4.6  vs.  51.3 ± 4.1; 
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FIGURE 3.15 IHC-NHERF1 intensity scores of TMA samples by groups. Mean intensity 
scores for NHERF1 are shown by the groups. ***P < 0.001 vs. left neighbor group. 
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FIGURE 3.16 IHC-NHERF1 staining of TMA samples by groups. Representative staining 
is shown. Note the overall decreases in IHC staining intensity for NHERF1 by groups, as 
defined; and a shifting trend of NHERF1 subcellular localization from strong cytoplasmic 
to strong nuclear from Group I to Group IV, respectively.  
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 All patients 
(n=39) 
Group I 
 
Group II 
 
Group III 
 
Group IV 
 
Sex, M:F 18:21 2:3 12:6 2:9 2:3 
Age, y  
(range) 
67.5 ± 2.4  
(37-90) 
70.8 ± 2.8 
(61-78) 
66.1 ± 4.1 
(37-86) 
70.4 ± 4.8 
(39-90) 
62.2 ± 5.4 
(41-72) 
      
Tumor grade 
(n=24)               
     
   1  6 (25%) 0 (0%) 2 (29%) 2 (22%) 2 (33%) 
   2 15 (63%) 2 (100%) 5 (71%) 5 (56%) 3 (50%) 
   3  3 (13%) 0 (0%) 0 (0%) 2 (22%) 1 (17%) 
 
TABLE 3.3 IHC-NHERF1intensity scores of TMA samples by groups and patient data. 
Sex, age, and tumor grade data are non-matched. Tumor grades are: 1, well 
differentiated; 2, moderately differentiated; 3, poorly differentiated. 
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 cytokeratin, 71.4 ± 3.8 vs. 50.9 ± 3.4; all P < 0.001) (FIGURES 3.17, 3.18, and 3.19, 
respectively). It may be taken that the grouping scheme used in this study specifically 
selected for epithelial tissue-rich tumor core (Groups I and II) against tissue-scarce 
invasive edges (Groups III and IV). The differences in NHERF1 intensity scores for all 
except between Group I and II may then reflect the differences in epithelial tissue 
content in the changing carcinoma background environment. The IHC-stained β-catenin, 
E-cadherin, and cytokeratin sections are shown in FIGURE 3.20, 3.21, and 3.22, 
respectively. β-catenin staining was mostly cytoplasmic, with variable but increased 
nuclear staining toward Group II, III, and IV. E-cadherin and cytokeratin did not have 
coherent staining patterns; many tissues lacked staining completely, whereas others 
stained strongly at membrane, or less frequently in the cytoplasm.  
 
3.2.2  IF analysis 
 
3.2.2.1  Nuclear localization analyses of NHERF1 
 
As the results of IHC analyses from both CRC cases and CRC TMA suggested 
that there may be nuclear species of NHERF1 in invasive carcinoma, quantitative 
confocal IF analysis was performed for co-localization between NHERF1, nuclear 
marker ToPro-3, and β-catenin. The results of this analysis are presented in FIGURE 3.23. 
Nuclear localization of NHERF1 as indicated by % co-localized voxels between 
NHERF1 and ToPro-3 was doubled between Group I and III (12.6 ± 4.3% vs. 24.2 ± 
2.8%, P< 0.05) and remained elevated in Group IV (12.6 ± 4.3% vs. 26.4 ± 3.3%, P < 
0.05), whereas nuclear localization of  β-catenin increased only non-significantly overall 
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FIGURE 3.17 IHC-β-catenin intensity scores of TMA samples by groups. Mean intensity 
scores for β-catenin are shown. ***P < 0.001 vs. left neighbor group. 
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FIGURE 3.18 IHC-E-cadherin intensity scores of TMA samples by groups. Mean 
intensity scores for E-cadherin are shown. ***P < 0.001 vs. left neighbor group. 
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FIGURE 3.19 IHC-cytokeratin intensity scores of TMA samples by groups. Mean 
intensity scores for cytokeratin are shown. ***P < 0.001 vs. left neighbor group. 
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FIGURE 3.20 IHC-β-catenin staining of TMA samples by groups. Serial sections to those 
presented in FIGURE 3.16 are shown.  
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FIGURE 3.21 IHC-E-cadherin staining of TMA samples by groups. Serial sections to 
those presented in FIGURE 3.16 are shown.  
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FIGURE 3.22 IHC-cytokeratin staining of TMA samples by groups. Serial sections to 
those presented in FIGURE 3.16 are shown.  
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FIGURE 3.23 Nuclear localization analysis of NHERF1 and β-catenin in TMA samples. 
Quantitative analysis of confocal IF imaging data is shown. Note increases in nuclear 
NHERF1 localization and in nuclear NHERF1/β-catenin co-localization in Groups III 
and IV. ‡P < 0.05 vs. Group I.  
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 (Group I: 18.2 ± 4.7% vs. Group IV: 31.5 ± 4.0%, P= NS). Nuclear co-localization of 
NHERF1 and β-catenin, on the other hand, increased significantly from Group I to IV 
(3.6 ± 1.8% vs. 10.4 ± 2.0%, P <0.05), and the tissue morphology was rather clear that 
those carcinomas in Group III and IV were increasingly more invasive than those in 
Group I and II. Selected few confocal images of double-stained TMA samples by 
NHERF1 and β-catenin are presented in FIGURE 3.24. 
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FIGURE 3.24 NHERF1 IF staining of TMA samples by groups. Confocal analysis is 
shown. NHERF1 (green) and β-catenin (red) co-stained. Cell nuclei were marked with 
ToPro-3 (blue). 
 
 
 
 3.3  CRC cell study 
 
3.3.1  Screening of human intestinal cells 
 
 To model the observed NHERF1 alterations in CRC specimens, a panel of six 
human intestinal cell lines was screened for NHERF1 expression (FIGURE 3.25). 
Subcellular fractionation analyses were also performed for each of these cell lines (data 
not shown); the results suggested that Caco-2, but none of the other cell lines, have 
polarized distribution of NHERF1 at the apical microvilli. Confocal IF analysis was then 
performed with Caco-2 cells in the confluent 2D monolayer; NHERF1 was indeed at the 
apical microvilli in these cells, as contrasted to E-cadherin which was localized at the 
basolateral membranes (FIGURE 3.26).  
 
3.3.2  NHERF1 knockdown in Caco-2 cells 
 
To mimic the NHERF1 loss in human colonic adenoma, NHERF1 in Caco-2 
cells were depleted by two constructs of shRNAs (sh1 and sh4). Efficient knockdown of 
NHERF1 induced notable cell scattering in both of the NHERF1-depleted cells (FIGURE 
3.27); and, as the changes in cell shape suggested epithelial-mesenchymal transition 
(EMT) in NHERF1-depleted cells as compared to the vector control, total cell lysates 
were probed for the epithelial marker E-cadherin and the mesenchymal marker 
fibronectin. We found moderate reduction in E-cadherin level, with a gain in fibronectin, 
in NHERF1-depleted cells (FIGURE 3.28). While total β-catenin level was unchanged in 
these cells, IF analysis of 2D monolayer showed significant reduction of membrane β-
catenin  (vector:  100.0 ± 4.4 %,  sh1:  58.4 ± 2.5 %,  sh4:  46.4 ± 2.1 %,  P < 0.05);  and 
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FIGURE 3.25 Screening of six CRC cell lines for NHERF1 expression. Western blot 
analysis of total cell lysates is shown. Proteins were loaded at 30 μg per lane. 
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FIGURE 3.26 Subcellular localization of NHERF1 in Caco-2 cells. Confocal IF analysis 
is shown. NHERF1 (red) and E-cadherin (green) co-stained. Note NHERF1 localized 
apically to E-cadherin E-cadherin is shown at the lateral cell-cell junctions in both XY 
(bottom) and Z sections (top). 
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FIGURE 3.27 NHERF1 depletion by two shRNAs (sh1 and sh4) in Caco-2 cells. Crystal 
violet staining and immunoblot analysis are shown. Note EMT-like morphological 
changes in NHERF1-depleted cells. Numbers under the lanes of immunoblot indicate 
NHERF1 levels relative to GAPDH.  
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FIGURE 3.28 EMT for NHERF1-depleted Caco-2 cells. Immunoblot analysis is shown 
with indicated EMT markers. Proteins were loaded at 30 μg per lane.  
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 nuclear β-catenin was concomitantly increased (vector: 100.0 ± 6.8 %, sh1: 235.2 ± 9.7 
%, sh4: 215.1 ± 9.2 %, P < 0.05) (FIGURE 3.29). In wound-healing assay, NHERF1-
depleted cells showed significantly faster migration than their vector control cells (vector: 
112 ± 8 μm/48h, sh1: 154 ± 9 μm/48h, sh4: 158 ± 6 μm/48h, P < 0.05) (FIGURE 3.30). 
They also showed increased invasive activity in transwell matrigel assay (vector: 54.0 ± 
11.8 cells/field, sh1: 139.3 ± 15.4 cells/field, P < 0.05) (FIGURE 3.31), and increased 
activities of secreted MMPs as shown by gelatin zymography (FIGURE 3.32).  
 
3.3.3   Re-establishment of epithelial phenotypes by Myr-NHERF1 
  
 To rescue the phenotypes of NHERF1-depleted Caco-2 cells, we expressed three 
variants of NHERF1 constructs: wild-type NHERF1, membrane-targeted Myr-NHERF1, 
and nuclear-targeted NLS-NHERF1. Western blot, confocal IF analysis, and 
corresponding proliferation assay for the cells expressing these three constructs are 
shown in FIGURE 3.33, FIGURE 3.34, and FIGURE 3.35, respectively. Reconstitution of 
NHERF1-depleted Caco-2 cells with membrane-targeted Myr-NHERF1 restored E-
cadherin at lateral cell-cell contacts, whereas both nuclear-targeted NLS-NHERF1 and 
wild-type wt-NHERF1 failed to restore E-cadherin. The corresponding immunoblot 
analysis also showed restoration of E-cadherin level only by Myr-NHERF1. Whereas no 
change in cell proliferation was induced by reconstitution with Myr-NHERF1, both 
NLS- and wt-NHERF1 increased cell proliferation significantly. Migration, invasion, 
and secreted MMP activities were also examined, but no increase could be detected 
beyond the already elevated level achieved by NHERF1 depletion. 
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FIGURE 3.29 Nuclear β-catenin in NHERF1-depleted Caco-2 cells. Confocal IF images 
and densitometric analysis of β-catenin intensity are shown. β-catenin (red) and E-
cadherin (green) co-stained. Cell nuclei were marked with ToPro-3 (blue). n=25. *P < 
0.05; ***P < 0.001 vs. Vector.  
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FIGURE 3.30 Migration assay in NHERF1-depleted Caco-2 cells. Quantitative analysis 
of scratch closures at 48h is shown. n=3. *P <0.05 vs. Vector.  
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FIGURE 3.31 Invasion assay in NHERF1-depleted Caco-2 cells. Quantitative analysis of 
invading cells through the matrigel substrate at 48h is shown. n=3. *P < 0.05 vs. Vector.  
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FIGURE 3.32 Gelatin zymography for NHERF1-depleted Caco-2 cells. Positive and 
negative controls are DMEM with and without FCS, respectively. Sample loading was 
normalized to cell numbers. 
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FIGURE 3.33 Wild-type NHERF1 overexpression in NHERF1-depleted Caco-2 cells. 
Confocal IF analysis showing reconstituted wild-type NHERF1 (red) in the cytoplasm, 
failing to restore E-cadherin (green) expression at the lateral membrane. Cell nuclei were 
marked with ToPro-3 (blue). Note corresponding increase in cell proliferation in cells 
overexpressing wild-type NHERF1. *P < 0.05. vs Vector. 
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FIGURE 3.34 Myr-NHERF1 overexpression in NHERF1-depleted Caco-2 cells. 
Confocal IF analysis showing reconstituted membrane-targeted Myr-NHERF1 (red) at 
the apical membrane, and E-cadherin (green) re-expression at the lateral membrane. Cell 
nuclei were marked with ToPro-3 (blue).  
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FIGURE 3.35 NLS-NHERF1 overexpression in NHERF1-depleted Caco-2 cells. 
Confocal IF analysis showing reconstituted nuclear-targeted NLS-NHERF1 (red) in the 
cytoplasm, failing to restore E-cadherin (green) expression at the lateral membrane. Cell 
nuclei were marked with ToPro-3 (blue). Note corresponding increase in cell 
proliferation in cells overexpressing wild-type NHERF1. ***P < 0.001. vs Vector. 
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 FIGURE 3.36 shows the crystal violet staining of Myr-NHERF1-reconstituted 
Caco-2 cells. Myr-NHERF1-reconstituted cells reverted to wild-type-like cell showing 
tight clustering of cells and dense nuclear staining by crystal violet, as compared to the 
more scattered and faintly-stained NHERF1-depleted cells. FIGURE 3.37 shows the 
wound-healing migration assay of Myr-NHERF1-and vector reconstituted cells. At 48h 
post-scratching, Myr-NHERF1-reconstituted cells migrated significantly less than vector 
control cells (vector: 176 ± 19 μm/48h, +Myr-NHERF1: 107 ± 13 μm/48h, P < 0.05). 
FIGURE 3.38 shows confocal IF analysis of β-catenin distribution in Myr-NHERF1-
reconstituted Caco-2 cells. Nuclear β-catenin decreased (vector: 100.0 ± 4.7 %, +Myr-
NHERF1: 43.4 ± 8.2 %, P < 0.001), whereas membrane β-catenin increased (vector: 
100.0 ± 6.2 %, +Myr-NHERF1: 146.3 ± 5.1 %, P < 0.001), in Myr-NHERF1 
reconstituted cells as compared to vector control. Concomitant increase in E-cadherin 
was also noted for Myr-NHERF1-reconstituted cells. 
 
3.3.4   Apical targeting of Myr-NHERF1 requires tail EB-region 
 
 FIGURE 3.39 shows confocal IF analysis of Myr-NHERF1 and Myr-PDZ1-2 
(carboxyl-terminal EB region deleted) expression in NHERF1-depleted Caco-2 cells. 
Whereas Myr-NHERF1 was localized exclusively at the apical membrane, Myr-PDZ1-2 
was concentrated at the lateral membranes, suggesting the requirement of EB region for 
targeting of NHERF1 to the apical plasma membrane. Differences in confluent cell 
monolayer morphology were also noted for these cells; phase contrast images are 
presented in FIGURE 3.40. 
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FIGURE 3.36 Epithelial-like morphology of Myr-NHERF1-reconstituted Caco-2 cells. 
Crystal violet staining is shown. Note tighter cell clustering and denser nuclear staining 
for sh1+Myr-NHERF1 cells than sh1+Vector cells. 
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FIGURE 3.37 Migration assay of Myr-NHERF1-reconstituted Caco-2 cells. Quantitative 
analysis of scratch closures at 48h is shown. n=3. *P <0.05 vs. Vector.  
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FIGURE 3.38 β-catenin redistribution in Myr-NHERF1-reconstituted Caco-2 cells. 
Confocal IF images and densitometric analysis of β-catenin intensity are shown. β-
catenin (red) and E-cadherin (green) co-stained. Cell nuclei were marked with ToPro-3 
(blue). n=25. ***P < 0.001 vs. Vector.  
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FIGURE 3.39 Apical vs. lateral distribution of Myr-NHERF1 and Myr-PDZ1-2. Confocal 
IF analysis is shown. NHERF1 (red)-stained. Cell nuclei were marked with ToPro-3 
(blue). 
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FIGURE 3.40 Confluent cell morphology with Myr-NHERF1 and Myr-PDZ1-2. Phase 
contrast analysis is shown. Note partial restoration of confluent cell morphology by Myr-
PDZ1-2 as compared to Myr-NHERF1. 
 
 
 
90 
 3.3.5  NHERF1-deplated Caco-2 cysts 
 
To investigate further the role of NHERF1 in epithelial morphogenesis, we 
collaborated with Dr. Alan Hall (Memorial Sloan-Kettering Cancer Center, NY) to 
establish the 3D morphogenesis assay. When embedded as single cell suspensions in 
matrigel, Caco-2 3D cysts formed a polarized spherical monolayer through successive 
divisions for 8-12 days (FIGURE 3.41). NHERF1 was only weakly expressed in the 
cytoplasm at single-cell stage, but it began to concentrate along the metaphase plate 
during mitosis, and even more strongly concentrated in a disc around the center of cell-
cell interface at the beginning of two-cell stage. It then remained tightly associated with 
this disc space until the lumen formed in the mature cyst (FIGURE 3.42). 
 
 NHERF1 depletion by shRNA induced severe disruption of the cyst morphology, 
with formation of large asymmetrical spheroids lacking the lumen, varying in individual 
cell shape, size, and alignment. Although these spheroids retained lateral cell junctions 
as marked by E-cadherin (adherens junctions protein), apical polarity as marked by Ezrin 
(actin-binding protein), aPKC (Par complex component), and ZO-1 (tight junctions 
protein) were all lost or inverted to outer periphery of the cyst structure. Apical 
(supranuclear) orientation of the Golgi apparatus as marked by GM130 (cis-Golgi matrix 
protein) was also randomly re-distributed throughout the spheroids. Basal polarity as 
marked by Laminin (basement membrane protein) was lost or detached from the 
basement membrane (FIGURE 3.43). β-catenin was markedly accumulated in the nucleus 
of these NHERF1-depleted spheroids (FIGURE 3.44). 
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FIGURE 3.41 Development of Caco-2 3D cyst. Confocal IF analysis is shown. The cells 
were fixed and stained, at 2-8 days post-plating in matrigel. Phospho-Histone H3-S10 
(red) and E-cadherin (green) co-stained. Cell nuclei were marked with ToPro-3 (blue). 
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FIGURE 3.42 Apical PM formation in Caco-2 cysts. Confocal IF analysis is shown. The 
cells were fixed and stained, at 2-8 days post-plating in matrigel. NHERF1 (red) and E-
cadherin (green) co-stained. Cell nuclei were marked with ToPro-3 (blue).  
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FIGURE 3.43 Loss of cell polarity in NHERF1-depleted Caco-2 spheroids. Confocal IF 
analysis with indicated polarity markers is shown. Cell nuclei were marked with ToPro-3 
(blue). 
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FIGURE 3.44 Nuclear β-catenin in NHERF1-depleted Caco-2 spheroids. Confocal IF 
analysis is shown. β-catenin (red) and E-cadherin (green) co-stained. Cell nuclei were 
marked with ToPro-3 (blue). Arrowheads indicate nuclear β-catenin.  
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 3.3.6  Polarized distributions of AKT and  PTEN in Caco-2 cysts 
 
 Immunoblot analysis of HA-tagged AKT overexpression and corresponding IF 
analysis of HA-AKT distribution in Caco-2 cysts are presented in FIGURE 3.45. 
Contrasting to apical NHERF1, HA-AKT was partly localized in the cytoplasm, with 
some noticeable concentrations at the basal membrane. Similar analyses of Caco-2 cysts 
with overexpressed Myc-tagged PTEN and PTEN-ΔPDZ (last three amino acids of 
PTEN deleted) are presented in FIGURE 3.46. While most of Myc-PTEN was localized in 
the cytoplasm and nucleus, a small fraction in some cysts was concentrated at the apical 
PM. Myc-PTEN-ΔPDZ tended to eliminate this apical concentration, with its increased 
concentrations in cell nuclei. In NHERF1-depleted spheroids, PTEN was localized 
predominantly in the cytoplasm. 
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FIGURE 3.45 Basal distribution of HA-AKT in Caco-2 cysts. Immunoblot of whole cell 
lysates shows HA-tagged AKT expression in Caco-2 cells. Proteins were loaded at 30 μg 
per lane. Endogenous (Endo.) AKT is indicated. Corresponding confocal IF analysis of 
Caco-2 cysts with HA (green) and NHERF1 (red) antibodies is shown. Note basal 
membrane distribution of HA-AKT (arrow).  
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FIGURE 3.46 Apical distribution of Myc-PTEN in Caco-2 cysts. Immunoblot of whole 
cell lysates shows Myc-tagged PTEN and PTEN-ΔPDZ expression in Caco-2 cells. 
Proteins were loaded at 30 μg per lane. Endogenous (Endo.) PTEN is indicated. 
Corresponding confocal IF analysis of Caco-2 cysts with PTEN (green) and NHERF1 
(red) antibodies, and similar analysis of NHERF1-depleted spheroids, is shown. Note 
apical membrane localization of Myc-PTEN in Caco-2 cyst (arrow).  
 
  
 
CHAPTER 4 
 
DISCUSSION 
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 4.1  Initial summary 
 
This study was undertaken to test the hypothesis that NHERF1 acts as a tumor 
suppressor in normal human colon, and therefore that it may be lost or altered in CRC. 
The results of our study indicate that the expression of NHERF1 protein and the 
development of CRC are indeed closely intertwined. NHERF1 is selectively localized at 
the apical membrane in normal human colonic mucosa, and may be a regulator of 
epithelial morphogenesis. NHERF1 loss, in this way, plays a role in the loss of normal 
epithelial phenotypes, and may contribute to colorectal tumorigenesis. NHERF1 is also 
ectopically overexpressed in some colonic carcinomas. This appears to increase tumor 
aggressiveness beyond the loss of NHERF1 alone, and may thereby contribute to CRC 
progression. The findings presented here provide insights not only in the general field of 
biology concerning cell polarity and junctional complex formation, but also have 
implications for the detection of colonic adenoma and the therapeutic management of 
advanced carcinoma. These points will be discussed in the paragraphs below.     
 
4.2  NHERF1 and epithelial morphogenesis 
 
NHERF1 was localized at the apical membrane in normal human colonic mucosa, 
but not in adjacent adenoma or carcinoma areas (see FIGURE 3.2-3.7). The noted 
selective expression of NHERF1 in these human specimens confirms the previous results 
in mice in which NHERF1 was detected at the apical microvilli of intestinal BBM 
(Ingraffea et al., 2002; Reczek et al., 1997). Given the primary function of apical 
microvilli to increase the surface area for fluid and electrolyte transport, defects in these 
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 structures due to NHERF1 deficiency may be expected to incur disturbances in the 
dynamics of the associated transport processes. It has been previously described that the 
pH profile is altered in many tumors, and this has been, so far, attributed to deregulated 
proton secreting activities of the Na+/H+ exchanger (NHE1) (Cardone et al., 2005). A 
topic that may be of future interest is the role of NHERF1 in the pH dynamics of 
intestinal enterocytes. NHERF1 as a co-regulator of NHE3 (Weinman et al., 1993; 
Weinman et al., 1995) may well have a functional involvement in this process. 
 
In a complementary cell-based study to examine the role of NHERF1 in CRC, 
we used human intestinal Caco-2 cells that express NHERF1 at the apical microvilli (see 
FIGURE 3.26). Depletion of NHERF1 in 2D cell monolayers induced characteristic 
migratory appearance and scattering of the cells suggestive of EMT, with loss of E-
cadherin, gain of fibronectin, and increase in nuclear β-catenin (see FIGURE 3.27-3.29). 
Our group has previously obtained similar results in a study of NHERF1-deficient MEFs 
(Kreimann et al., 2007). The finding in MEFs appeared to reflect the loss of direct 
interaction between NHERF1 and β-catenin. However, the same two proteins in Caco-2 
cells are sequestered in distant cellular compartments; the likeliness of their direct 
interaction is thereby limited in this case. It is possible that NHERF1 deficiency 
indirectly induces tyrosine phosphorylation of β-catenin for uncoupling from E-cadherin 
(Lilien and Balsamo, 2005). An alternative possibility is the cross-activation of β-catenin 
by the activation of Akt and/or inhibition of glycogen synthase kinase-3β (GSK3β) 
(Larue and Bellacosa, 2005). Whatever is the case, β-catenin release may then induce E-
cadherin downregulation through endocytosis (Bryant and Stow, 2004), or perhaps 
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 through activation of the TCF/LEF complex to increase E-cadherin transcriptional 
repressors such as Snail and Slug (Nelson and Nusse, 2004). 
 
Unlike those cells in 2D monolayers, NHERF1-depleted cells in 3D 
morphogenesis assay did not decrease E-cadherin level, yet nuclear shift of β-catenin 
was still evident (see FIGURE 3.44). The discrepancy in the results of 2D and 3D assays 
is difficult to explain, but may be taken that the change in β-catenin, rather than in E-
cadherin, is the more primary and less variable consequence of NHERF1 deficiency in 
CRC cells. From a technical standpoint, the noted absence of E-cadherin in NHERF1-
depleted cells in 3D assay is a single disqualifying criterion for these cells in the classic 
EMT (Thiery, 2002). Importantly, however, the fact has been often underscored that 
many of the epithelial cell features are also retained even in the most advanced 
carcinoma specimens. It is of interest that a semi-quantitative scoring system was 
recently proposed for the evaluation of EMT in epithelial carcinomas; this is represented 
by the scale of 0 (minimal transition) to 3 (full transition), based on cell polarity, cell 
cohesiveness, and the expressions of keratin and vimentin filaments (Klymkowsky and 
Savagner, 2009). The phenotypes of NHERF1-depleted cells in our 3D morphogenesis 
assay fitted remarkably well in the level 1 category: that “most tumor cells display loss 
of cell polarity, but retain cohesive cell-cell contacts and keratin expression”. 
 
NHERF1-depleted cells in 3D morphogenesis assay displayed indeed severe loss 
of cell polarity. In this loss, apical-tight junction markers such as ezrin, aPKC, and ZO-1 
were all shifted “inside-out” to the periphery of the cyst structures, whereas basement 
membrane marker, laminin, was detached from the basal surface out to ECM medium 
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 (see FIGURE 3.43). Somewhat unexpectedly, our results were most comparable with two 
of those previous studies that addressed the collagen I-β1-integrin-Rac1 pathway in 
Madin-Darby canine kidney (MDCK) cells (O'Brien et al., 2001; Yu et al., 2005). In 
these studies, inhibition of the pathway by the addition of β1-integrin blocking antibody 
or by the expression of a dominant negative mutant of Rac1 led to the failure of laminin 
assembly and, as in our study, resulted in the “inside-out” loss of apical-basal polarity. 
Although NHERF1, laminin, and the components of the collagen I-β1-integrin-Rac1 
pathway are all too distant from one to another to have direct mechanism of interactions, 
many possibilities remain open for indirect mechanism. We will first seek the 
consequence of NHERF1 interaction with PTEN (see FIGURE 3.45-3.46), which itself 
has been required for the establishment of apical polarity (Martin-Belmonte et al., 2007). 
This may be, in turn, indirectly involved with Rac1 (Martin-Belmonte and Mostov, 
2007). 
 
4.3  NHERF1 loss and ectopic overexpression 
 
Over 90% of adenomas in this study had losses of NHERF1 expression as 
compared to normal mucosa, yet approximately half of the matched carcinomas had 
overt NHERF1 overexpression in the cytoplasm (see FIGURE 3.5). It appears that 
NHERF1 synthesis and/or its degradation is profoundly altered during colorectal 
tumorigenesis, but the mechanism of this alteration is not presently known. NHERF1 
overexpression has been previously reported in several studies of human tumors, namely 
breast cancer (Cardone et al., 2007; Mangia et al., 2009; Song et al., 2007; Stemmer-
Rachamimov et al., 2001), hepatocellular carcinoma (Shibata et al., 2003), and 
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 Schwannoma (Fraenzer et al., 2003). In our cell-based study, NHERF1 overexpression 
in cells already depleted with NHERF1 conferred additional growth advantage (see 
FIGURE 3.33-3.35). It is possible that ectopically overexpressed NHERF1 forms a 
complex in this new compartment with molecule(s) that promotes cell growth. One such 
candidate is β-catenin, to which NHERF1 associates directly in vivo (Kreimann et al., 
2007; Shibata et al., 2003). This idea was supported by our preliminary study which co-
immunoprecitated β-catenin with NHERF1 in CRC cells that expressed NHERF1 in the 
cytoplasm (data not shown). As also noted in the present study, these two proteins were 
co-localized in up to one-third of nuclear β-catenin pool in CRC TMA (see FIGURE 3.23).  
 
4.4  Theoretical and clinical considerations 
 
The findings from our study provide several insights to the field of cell biology at 
large; central to this theme is the role of NHERF1 as a regulator of epithelial 
morphogenesis. It is striking, even somewhat unexpected, that peripheral presence of 
this small adaptor protein with no known enzymatic activities has such profound effect 
on a fundamental cellular process as cell polarization. It is also surprising, though the 
indications are clear, that there is no functional redundancy for this small yet important 
protein. Possible answers to these questions may lie in the idea that NHERF1 as a PDZ 
protein is capable of multimerization (Harris and Lim, 2001), that gives it both 
complexity and uniqueness of context not easily replicated by even most closely related 
NHERF family proteins. Another consideration is that many coordinate PDZ proteins 
are, like NHERF1, targeted to different membrane domains of polarized epithelial cells 
(Fanning and Anderson, 1999a; Fanning and Anderson, 1999b; Nourry et al., 2003). It 
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 appears that these scaffolds would then functionally interact, and are integrated into a 
single polarity pathway (Bilder et al., 2003; Tanentzapf and Tepass, 2003). The role of 
NHERF1 in this pathway remains yet to be uncovered. In this interest, Sip1, a 
Drosophila homolog of NHERF1, was recently identified (Hughes et al., 2010). A 
possible screening approach for the interacting partners of NHERF1 will be to use the 
genetic tools available in this Drosophila model. 
 
On a more clinical note, EMT that appears to be induced by NHERF1 deficiency 
can be considered an attractive target for cancer therapy. The traditional expectation 
would have been that inhibition of EMT might intervene with cancer metastasis and with 
problematic chemoresistance that is characteristic of this transdifferentiation process 
(Polyak and Weinberg, 2009). Lately, however, EMT is also increasingly discussed in 
the context of acquired cell stemness (Brabletz et al., 2005; Mani et al., 2008). Cancer 
cell stemness by the definition of the term is the cell’s ability to seed new tumors (Reya 
et al., 2001). In this modified term, inhibition of EMT would intervene with 
tumorigenesis, in fact exactly as we observed in our experimental context.  
 
4.5  Future aims 
 
4.5.1  Mechanism of NHERF1 loss in colorectal tumorigenesis 
 
The mechanism of NHERF1 loss during colorectal tumorigenesis remains 
unclear. Two scenarios, that this either involves genomic or epigenetic instability, are 
probably most likely (Grady and Carethers, 2008). It is of our interest that the 
preliminary sequence analysis of human genomic NHERF1 (NG_013022) indicated 
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 dense CpG islands in the 5’ promoter region (data not shown). This promoter region may 
be subject to aberrant DNA methylation during colorectal tumorigenesis, as are a panel 
of other markers that have shown clinical potential in being used non-invasively as fecal 
DNA-based screening tests (Chan et al., 2002; Li et al., 2003; Petko et al., 2005; Rashid 
et al., 2001). One might approach this experiment in three ways: first, to verify that 
NHERF1 silencing does indeed occur epigenetically; that is, silencing occurs at the 
transcript level and that this involves no changes in the coding region of NHERF1. Next, 
the location of methylated cysteines will be identified in CRC specimens and/or CRC 
cell lines by bisulfite sequencing. DNA demethylating agent can then be used to treat 
CRC cells, and changes in cell phenotype to be evaluated. 
 
4.5.2  Role of cytoplasmic and nuclear NHERF1 in colorectal cancer invasion 
 
On the basis of results from histological studies in CRC specimens, we postulate 
that the cells with nuclear NHERF1 and to a less extent cytoplasmic NHERF1, too, are 
more invasive, metastatic, and stem-cell like than those without NHERF1 alone. 
However, in vitro migration and invasion experiments have not been thus far conductive 
in discriminating NHERF1-depleted cells from those ectopically overexpressing 
NHERF1 (data not shown). The failure of these experiments might reflect the limitation 
in sensitivity of these in vitro assays, and/or in difficulty of the cell culture system to 
adequately reproduce the components of tumor microenvironment. Additional battery of 
tumorigenesis and metastasis assays will be attempted next, including soft agar assay to 
examine anchorage-independent growth; implantation and tail vein injection of the cells 
in immunodeficient mice to examine tumorigenesis and metastasis in vivo; and 2D 
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 and/or 3D chemoresistance/apoptosis assay with 5-fluorouracil (5-FU). As we also 
postulate that nuclear NHERF1 associates with β-catenin to cooperate in the activation 
of the Wnt/β-catenin pathway, double-IF staining will be performed to evaluate co-
localization between these two proteins. Cell nuclear fraction will be also extracted to 
evaluate complex formation by co-immunoprecipitation; and TOP/FOP luciferase assay 
will be performed to evaluate β-catenin-specific transcriptional activity.    
 
4.5.3  Cooperation between NHERF1 and β-catenin in ApcMin/+ mouse model 
 
We began to cross C57BL/6J ApcMin/+ mice from the Jackson Laboratory with 
our NHERF1(-/-) mice inbred in the same background. The Min mice develop multiple 
intestinal neoplasia due to a truncating mutation at T2549A, similarly to those in FAP 
and sporadic CRC patients, and are thus commonly used as the mouse model of 
intestinal cancer (Moser et al., 1990; Su et al., 1993). The analysis of the first 53 mice 
showed that median survival was significantly reduced in NHERF1(-/-)/ApcMin/+ mice as 
compared to NHERF1(+/+)/ApcMin/+ and NHERF1(+/-)/ApcMin/+  mice (19 vs. 29 and 30 
weeks, P <0.001). Efforts are now directed at characterization of the tumor development 
in these mice by the assessment of location, number, size, grade, and metastatic potential 
of the tumors. To evaluate also the contribution of the Wnt/β-catenin pathway to the 
pathogenesis of these tumors, tissue staining will be performed with Wnt/β-catenin-
specific markers. Tissue will be additionally profiled by the known β-catenin target 
genes by quantitative RT-PCR of crypt-villus axis fractions. 
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 4.6  Conclusions 
 
This study shows that the development of human CRC is closely associated with 
progressive changes in the expression of NHERF1 protein (FIGURE 4.1). NHERF1 
appears as an important regulator of epithelial morphogenesis when localized at the 
apical membrane. NHERF1 loss and ectopic expression that induce massive disruption 
of epithelial polarity may, thereby, contribute to CRC progression. Future studies will 
aim to clarify the mechanism of NHERF1 downregulation in adenoma, and characterize 
greater phenotypic details of ectopic NHERF1 overexpression in advanced carcinoma. 
As part of complementary effort to these, studies are also under way to address the 
cooperation between NHERF1 deficiency and the Wnt/β-catenin pathway activation in 
the ApcMin/+ mouse model of colorectal cancer.   
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FIGURE 4.1 Model of NHERF1 role in CRC development. Note the initiating loss of 
NHERF1 from apical plasma membrane in normal colonic mucosa to induce the 
formation of benign adenoma. Ectopic re-expression of NHERF1 in the cytoplasm and 
nucleus further promotes CRC progression, possibly through cooperative interaction 
between NHERF1 and β-catenin. The lower panel scheme depicts the experimental 
strategies used in this thesis to model NHERF1 loss and re-expression in cultured 
intestinal epithelial cells (IECs). 
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